District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033
Recruiting
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: Georgetown University, Washington, District of Columbia
Conditions: Locally Advanced Pancreatic Cancer
Register for Updates
Shared-Decision Making for Hydroxyurea
NCT03442114
Recruiting
The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into account medical evidence and parent values and preferences). The study will compare two methods to help clinicians facilitate this-a clinician pocket guide and a clinician hydroxyurea shared decision making toolkit-in a group of parents of children ages 0-5 with sickle cell disease. The investigators hope t... Read More
Gender:
All
Ages:
Between 1 month and 5 years
Trial Updated:
02/09/2022
Locations: Howard University, Washington, District of Columbia
Conditions: Sickle Cell Anemia, Children, Only
Register for Updates
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
NCT04452565
Recruiting
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2022
Locations: Coronavirus Research Institute-Testing Site, Washington, District of Columbia
Conditions: Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Register for Updates
The EMPOWER Study: Endometriosis Diagnosis Using microRNA
NCT04598698
Recruiting
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. Participants will undergo 2 study visi... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
01/11/2022
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Endometriosis
Register for Updates
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Solid Tumors, GI Cancer
Register for Updates
Improving Treatment and Recovery Services for Individuals With Opioid Problems
NCT05129813
Recruiting
Participants include persons receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center or buprenorphine treatment by telemedicine and Recovery Guide counseling in a church or faith-based community organization. Participants are interviewed at the outset of treatment, after 4 to 6 weeks, and then at 10 to 12 weeks of treatment. The study is an observational study aimed at evaluating the experiences and response to treatment of participants.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/19/2021
Locations: Howard University, Washington, District of Columbia
Conditions: Counseling
Register for Updates
Pediatric Boot Camp Program
NCT05066893
Recruiting
An intensive 13 weeks program that aims to improve glucose control in children with type 1 diabetes.
Gender:
All
Ages:
Between 11 years and 18 years
Trial Updated:
09/23/2021
Locations: Medstar Pediatrics, Washington, District of Columbia
Conditions: Type 1 Diabetes, Children, Only
Register for Updates
GARNET™ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection
NCT04658017
Recruiting
To evaluate the feasibility of performing combined hemodialysis with the GARNET device in chronic hemodialysis patients with a blood stream infection (BSI), and measure clinical performance and safety endpoints.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
09/01/2021
Locations: George Washington University, Washington, District of Columbia
Conditions: Bloodstream Infection
Register for Updates
Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder
NCT04850664
Recruiting
Opioid Use Disorders (OUD) cause significant burden to individuals, families, and the society. Our product - Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) - offers a cost-saving, home-based, user-friendly brain stimulation system that increased 6-month treatment retention of OUDs in a pilot study; and also, acutely reduced opioid withdrawal severity and negative affect during induction into opioid maintenance therapy. This study will establish its effectiveness in a broad... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
07/30/2021
Locations: Clinics of Dr. Edwin Chapman @ MHDG, Washington, District of Columbia
Conditions: Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity
Register for Updates
Brain-based Understanding of Individual Language Differences After Stroke
NCT04991519
Recruiting
Strokes often cause a loss of communication ability, referred to as aphasia, as well as cognitive difficulties. Each stroke survivor has a unique pattern of strengths and weaknesses in communication and cognition, and a unique course of recovery. The BUILD study aims to understand the brain basis of these individual differences in stroke outcome. Participants with stroke as well as controls matched in age, educational background, race, and sex are examined using a combination of standardized and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/27/2021
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Aphasia, Stroke, Alexia
Register for Updates
Prospective US Radiofrequency SUI Trial
NCT04720352
Recruiting
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pa... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/19/2021
Locations: Emerson Clinical Research Institute, Washington, District of Columbia
Conditions: Urinary Incontinence, Stress
Register for Updates
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
NCT04948151
Recruiting
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.
Gender:
Female
Ages:
21 years and above
Trial Updated:
06/24/2021
Locations: Intimmedicine Specialists, Washington, District of Columbia
Conditions: Female Sexual Arousal Disorder
Register for Updates